diaDexus, Inc. to Report Fourth Quarter and Full Year 2014 Financial Results on March 11, 2015

diaDexus, Inc. to Report Fourth Quarter and Full Year 2014 Financial Results on March 11, 2015

ID: 376259

Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)


(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/04/15 -- diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will report fourth quarter and full year 2014 financial results on Wednesday, March 11, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and provide a business update.

To access the webcast, visit the Company's website at . To access the conference call, dial 1 (855) 666-6874 for domestic callers and (262) 912-6259 for international callers. The reservation number for both is 86573797. A replay of the webcast will be available shortly following the live webcast for a period of four weeks.



diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The Company's two diagnostic products are the only FDA-cleared Lp-PLA2 blood tests to uncover the hidden risk of cardiovascular disease. The PLAC® Test ELISA Kit is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The PLAC® Test for Lp-PLA2 Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease in patients with no prior history of cardiovascular events, which represents approximately 75% of coronary heart disease patients. The Company also has heart failure biomarkers for development. For more information, please visit the Company's website at .



CONTACT:
Amy Figueroa, CFA
650-246-6424
Investor Relations and Corporate Communications





Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Taconic Biosciences Support Helps to Advance Rare Disease Research Flamel Technologies to Present at Two Upcoming Investor Conferences
Bereitgestellt von Benutzer: Marketwired
Datum: 04.03.2015 - 21:00 Uhr
Sprache: Deutsch
News-ID 376259
Anzahl Zeichen: 0

contact information:
Town:

SOUTH SAN FRANCISCO, CA



Kategorie:

Drugs



Diese Pressemitteilung wurde bisher 215 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"diaDexus, Inc. to Report Fourth Quarter and Full Year 2014 Financial Results on March 11, 2015"
steht unter der journalistisch-redaktionellen Verantwortung von

diaDexus, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Diadexus, Inc. to File Chapter 7 ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/10/16 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in assessing the prognosis of cardiac disease, today announced that it is filing for relief ...

Diadexus, Inc. Reports First Quarter 2016 Financial Results ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/28/16 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first q ...

Alle Meldungen von diaDexus, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z